Middle East Pharmaceutical Industries Co. has secured exclusive regional rights to register and commercialize Bio-Thera Solutions' proposed Dupixent biosimilar. The 15-year licensing deal strengthens Saudi Arabia's specialty biologics market and advances local manufacturing capabilities.
Middle East Pharmaceutical Industries Co., operating as Avalon Pharma, has secured an exclusive licensing agreement with Bio-Thera Solutions Inc. to register and commercialize a proposed biosimilar version of Dupixent across Saudi Arabia and the Middle East and North Africa region. The 15-year partnership includes framework provisions to transfer technology for local manufacturing, with commercial launch scheduled for 2031 pending patent clearance. Projections indicate cumulative revenues will reach at least SAR 400 million during the first seven years of commercial availability.
Based in Saudi Arabia, Middle East Pharmaceutical Industries Co. is a publicly listed pharmaceutical manufacturer specializing in consumer health, prescription dermatologicals, and specialty medicines. Bio-Thera Solutions Inc. is a global biopharmaceutical enterprise focused on researching, developing, and commercializing innovative biologics and biosimilars.
The partnership expands patient access to advanced biopharmaceutical therapies across regional markets while creating long-term commercial opportunities for healthcare distributors. Integrating biosimilar treatments into local supply chains directly supports Saudi Vision 2030 initiatives, which emphasize industrial localization and domestic health security. Commercializing complex therapeutics within regional borders helps insulate local healthcare systems from global supply volatility.
This commercial alliance underscores growing investment in specialty medicine across the regional pharmaceutical market. Technology transfer mechanisms established in the agreement position local manufacturers to build long-term technical expertise in biologics processing. Healthcare investors and pharmaceutical firms will gain expanded access to high-growth therapeutic markets, strengthening local competitiveness against global biopharmaceutical benchmarks.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.